UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents

Liver international, 2015-10, Vol.35 (10), p.2222-2227

2015

Volltextzugriff (PDF)

Cost‐effectiveness of generic pan‐genotypic sofosbuvir/velpatasvir versus genotype‐dependent direct‐acting antivirals for hepatitis C treatment

Journal of gastroenterology and hepatology, 2018-12, Vol.33 (12), p.2029-2036

2018

Volltextzugriff (PDF)

Direct-acting antivirals for RSV treatment, a review

Antiviral research, 2024-09, Vol.229, p.105948, Article 105948

2024

Volltextzugriff (PDF)

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV

International journal of medical arts, 2021-07, Vol.3 (3), p.1694-1699

2021

Volltextzugriff (PDF)

Direct-Acting Antiviral Therapy Effect on Extrahepatic Rheumatic Manifestations in Egyptian Chronic Hepatitis C (HCV) Patients

The Egyptian journal of hospital medicine, 2021-10, Vol.85 (1), p.3235-3340

2021

Volltextzugriff (PDF)

Anti-hepatitis C virus drugs and kidney

World journal of hepatology, 2016-11, Vol.8 (32), p.1343-1353

2016

Volltextzugriff (PDF)

Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

BMC gastroenterology, 2024-01, Vol.24 (1), p.49-16, Article 49

2024

Volltextzugriff (PDF)

Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C

Diagnostics (Basel), 2020-12, Vol.10 (12), p.1037

2020

Volltextzugriff (PDF)

Controlling HCV in Switzerland: running against the clock

Swiss medical weekly, 2019-03

2019

Volltextzugriff (PDF)

Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents

Alimentary pharmacology & therapeutics, 2017-11, Vol.46 (10), p.992-1000

2017

Volltextzugriff (PDF)

Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale‐up of direct‐acting anti‐viral therapy in community drug services: real‐world data

Addiction (Abingdon, England), 2021-10, Vol.116 (10), p.2893-2907

2021

Volltextzugriff (PDF)

Era of direct acting anti-viral agents for the treatment of hepatitis C

World journal of hepatology, 2018-10, Vol.10 (10), p.670-684

Ahmed, Monjur

2018

Volltextzugriff (PDF)

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

BMC infectious diseases, 2020-04, Vol.20 (1), p.264-10, Article 264

2020

Volltextzugriff (PDF)

Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report

Canadian journal of kidney health and disease, 2021-01, Vol.8, p.20543581211033496-20543581211033496

2021

Volltextzugriff (PDF)

Hepatitis C and Treatment in Patients with Chronic Kidney Disease

Disease-a-month, 2021-02, Vol.67 (2), p.101017, Article 101017

2021

Volltextzugriff (PDF)

Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients

International journal of clinical pharmacy, 2018-06, Vol.40 (3), p.693-699

2018

Volltextzugriff (PDF)

An overview of the Hepatitis C control plan in Qatar

Eastern Mediterranean health journal, 2019-01, Vol.25 (5), p.362-365

2019

Volltextzugriff (PDF)

Treatment of Genotype 3 Chronic Hepatitis C Virus Infection

Clinical Medicine Insights: Therapeutics, 2017-03, Vol.2017 (9), p.1-7-002

2017

Volltextzugriff (PDF)

Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir

Biomedical reports, 2019-03, Vol.10 (3), p.156-9

2019

Volltextzugriff (PDF)

Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis

International journal of rheumatic diseases, 2019-04, Vol.22 (4), p.592-598

2019

Volltextzugriff (PDF)

Ribavirin: How Does it Work and is it Still Needed?

Current hepatitis reports, 2011-09, Vol.10 (3), p.168-178

2011

Volltextzugriff (PDF)

The impact of using hepatitis c virus nucleic acid test–positive donor hearts on heart transplant waitlist time and transplant rate

The Journal of heart and lung transplantation, 2019-11, Vol.38 (11), p.1178-1188

2019

Volltextzugriff (PDF)

Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response

Journal of the Chinese Medical Association, 2023-09, Vol.86 (9), p.795-805

2023

Volltextzugriff (PDF)

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides

Virology (New York, N.Y.), 2015-02, Vol.476, p.168-179

2015

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents

Cost‐effectiveness of generic pan‐genotypic sofosbuvir/velpatasvir versus genotype‐dependent direct‐acting antivirals for hepatitis C treatment

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase

Direct-acting antivirals for RSV treatment, a review

Assessment of Left Ventricular Systolic Function by Speckle Tracking in Diabetic Patients Receiving Direct Acting Antiviral Drugs for Chronic HCV

Direct-Acting Antiviral Therapy Effect on Extrahepatic Rheumatic Manifestations in Egyptian Chronic Hepatitis C (HCV) Patients

Anti-hepatitis C virus drugs and kidney

Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong

Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C

Controlling HCV in Switzerland: running against the clock

Barriers to hepatitis C treatment in the era of direct‐acting anti‐viral agents

Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale‐up of direct‐acting anti‐viral therapy in community drug services: real‐world data

Era of direct acting anti-viral agents for the treatment of hepatitis C

Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

Expanding the Deceased Donor Pool in Manitoba Using Hepatitis C-Viremic Donors: Program Report

Hepatitis C and Treatment in Patients with Chronic Kidney Disease

Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients

An overview of the Hepatitis C control plan in Qatar

Treatment of Genotype 3 Chronic Hepatitis C Virus Infection

Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir

Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis

Ribavirin: How Does it Work and is it Still Needed?

The impact of using hepatitis c virus nucleic acid test–positive donor hearts on heart transplant waitlist time and transplant rate

Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response

Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides

Suchergebnisse filtern